Immunogenicity Comparison of Conjugate Vaccines Composed of Alginate and Lipopolysaccharide of Pseudomonas Aeruginosa Bound to Diphtheria Toxoid

Overview

Journal Iran J Microbiol

Publisher Tehran University of Medical Sciences

Specialty Infectious Diseases

Date 2015 Apr 8

PMID 25848521

Citations 3

Authors

Faezeh Najafzadeh

Ghazaleh Jaberi

Reza Shapouri

Mehdi Rahnema

Ashraf Karimi-Nik

Anvarsadat Kianmehr

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Treatment of Pseudomonas aeruginosa infections is greatly hampered by innate and acquired antibiotic resistance. The goal of this study was to compure the immunogenicity of conjugates of P. aeruginosa depolymerized alginate-diphtheria toxoid (D-ALGDT) and P. aeruginosa detoxified lipopolysaccharidediphtheria toxoid (D-LPSDT) in mouse model.

Materials And Methods: Alginate and LPS were purified from P. aeruginosa strain PAO1. The resulting depolymerized alginate (D-ALG) and detoxified LPS (D-LPS) were covalently coupled to diphtheria toxoid (DT) as a carrier protein with adipic acid dihydrazide (ADH) as a spacer molecule and carbodiimide as a linker. Sterility, safety and pyrogenicity tests were performed. 30 mice in two groups were immunized intraperitoneally on days 0, 14 and 28 with 10 μg of D-ALGDT and D-LPSDT. Conjugates specific antibody levels were also determined by enzyme-linked immunosorbent assay (ELISA).

Results: The conjugates were non-toxic and non-pyrogenic. Conjugates of D-ALGDT and D-LPSDT were shown to be safe and to elicit total IgG, IgM, IgA, IgG1, IgG2a, IgG2b and IgG3 antibodies in mice. ELISA results indicated that antibodies titer of D-ALGDT was more than D-LPSDT.

Conclusion: Immunization with D-ALGDT showed significant increase in all types of antibodies titers in versus D-LPSDT, suggesting D-ALGDT as a vaccine candidate against P. aeruginosa infections.

Citing Articles

Pseudomonas aeruginosa PAO1 outer membrane vesicles-diphtheria toxoid conjugate as a vaccine candidate in a murine burn model.

Zare BanadKoki E, Rasooli I, Ghazanfari T, Siadat S, Shafiee Ardestani M, Owlia P Sci Rep. 2022; 12(1):22324.

PMID: 36566282 PMC: 9789887. DOI: 10.1038/s41598-022-26846-z.

Preparation and immunological properties of a nanovaccine against based on gold nanoparticles and detoxified lipopolysaccharide.

Najafzadeh F, Tanomand A, Haddadi A, Majidi J Iran J Basic Med Sci. 2021; 24(2):203-212.

PMID: 33953860 PMC: 8061318. DOI: 10.22038/ijbms.2020.50732.11550.

Understanding -Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Sainz-Mejias M, Jurado-Martin I, McClean S Cells. 2020; 9(12).

PMID: 33291484 PMC: 7762141. DOI: 10.3390/cells9122617.

References

Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A . Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiol. 2010; 10:9. PMC: 2820439. DOI: 10.1186/1471-2180-10-9. View

Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, Moazzeni M, Esmaeeli Djavid G . Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J Med Microbiol. 2006; 55(Pt 10):1441-1446. DOI: 10.1099/jmm.0.46696-0. View

Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y . Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007; 13(6):560-78. DOI: 10.1111/j.1469-0691.2007.01681.x. View

Cryz Jr S, Sadoff J, Furer E, Germanier R . Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis. 1986; 154(4):682-8. DOI: 10.1093/infdis/154.4.682. View

Rezania S, Amirmozaffari N, Tabarraei B, Jeddi-Tehrani M, Zarei O, Alizadeh R . Extraction, Purification and Characterization of Lipopolysaccharide from Escherichia coli and Salmonella typhi. Avicenna J Med Biotechnol. 2013; 3(1):3-9. PMC: 3558174. View

Said A, Livermore D, Williams R . Expression of H1 outer-membrane protein of Pseudomonas aeruginosa in relation to sensitivity to EDTA and polymyxin B. J Med Microbiol. 1987; 24(3):267-74. DOI: 10.1099/00222615-24-3-267. View

Konadu E, Robbins J, Shiloach J, Bryla D, Szu S . Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun. 1994; 62(11):5048-54. PMC: 303225. DOI: 10.1128/iai.62.11.5048-5054.1994. View

Kipnis E, Sawa T, Wiener-Kronish J . Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006; 36(2):78-91. DOI: 10.1016/j.medmal.2005.10.007. View

Midwinter A, Faine S, Adler B . Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived immuno-conjugates from Leptospira interrogans. J Med Microbiol. 1990; 33(3):199-204. DOI: 10.1099/00222615-33-3-199. View

10.

Gupta R, Szu S, Finkelstein R, Robbins J . Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun. 1992; 60(8):3201-8. PMC: 257302. DOI: 10.1128/iai.60.8.3201-3208.1992. View

11.

STANISLAVSKY E, Lam J . Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol Rev. 1998; 21(3):243-77. DOI: 10.1111/j.1574-6976.1997.tb00353.x. View

12.

Goldstein J, Hoffman T, Frasch C, Lizzio E, BEINING P, Hochstein D . Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect Immun. 1992; 60(4):1385-9. PMC: 257008. DOI: 10.1128/iai.60.4.1385-1389.1992. View

13.

Seid Jr R, Sadoff J . Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J Biol Chem. 1981; 256(14):7305-10. View

14.

Kossaczka Z, Shiloach J, Johnson V, Taylor D, Finkelstein R, Robbins J . Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun. 2000; 68(9):5037-43. PMC: 101731. DOI: 10.1128/IAI.68.9.5037-5043.2000. View

15.

Cryz Jr S, Furer E, Cross A, Wegmann A, Germanier R, Sadoff J . Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest. 1987; 80(1):51-6. PMC: 442200. DOI: 10.1172/JCI113062. View

16.

Gupta R, Egan W, Bryla D, Robbins J, Szu S . Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun. 1995; 63(8):2805-10. PMC: 173380. DOI: 10.1128/iai.63.8.2805-2810.1995. View

17.

Holder I . Pseudomonas immunotherapy: a historical overview. Vaccine. 2004; 22(7):831-9. DOI: 10.1016/j.vaccine.2003.11.028. View

18.

Pier G . Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol. 2007; 297(5):277-95. PMC: 1994162. DOI: 10.1016/j.ijmm.2007.03.012. View

19.

Watson D, Robbins J, Szu S . Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun. 1992; 60(11):4679-86. PMC: 258218. DOI: 10.1128/iai.60.11.4679-4686.1992. View

20.

Weintraub A . Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003; 338(23):2539-47. DOI: 10.1016/j.carres.2003.07.008. View